¿Qué relación existe entre la otitis y el colesteatoma?

Respuesta generada por Itaca · 50 fuentes · 2 de enero de 2026

Pregunta original

colestheatoma otitis

Summary

Cholesteatoma in the context of otitis media is a benign, keratinizing epithelial lesion in the middle ear or mastoid, often acquired due to chronic suppurative otitis media (CSOM), leading to bone erosion, hearing loss, and potential complications. It requires surgical excision as primary treatment, with imaging (HRCT/MRI) aiding diagnosis; prevalence is approximately 10 per 100,000, higher in CSOM cases.[1][2][3]

Definition and Classification

Cholesteatoma is defined as the presence of keratinizing squamous epithelium in the middle ear or mastoid space, forming a cystic structure filled with keratin debris over a fibrous stroma.[3][1][4] It is not neoplastic or cholesterol-containing.[1]

  • Acquired: Most common, linked to Eustachian tube dysfunction, chronic otitis media, retractions, or perforations (e.g., atticoantral type).[1][5][6]
  • Congenital: Rare, epithelial inclusion behind intact tympanic membrane without otitis history; often asymptomatic initially.[7][5][8]
  • Subtypes: Primary (pars flaccida), secondary (migration via perforation), external auditory canal (rare).[3][9]

EAONO/JOS consensus classifies by location, extent, and staging for surgical outcomes.[10]

Epidemiology and Prevalence

Incidence of acquired cholesteatoma is 9.2-10 per 100,000 annually.[1][5] In CSOM cohorts, 30% may have cholesteatoma, with 45% pediatric cases and male predominance (70%).[3][11] Peaks at 5-15 years; overlaps with otitis media incidence, delaying diagnosis.[12] Higher in chronic ear disease; Brazilian study: 419 cases showed hypoacusis/otorrhea as typical.[11]

Clinical Presentation and Risk Factors

Common: Foul-smelling otorrhea, hearing loss, ear fullness; complications include ossicular destruction, facial palsy, vertigo, labyrinthine/intracranial issues (e.g., abscess, meningitis).[1][13][14] Risk factors: Chronic otitis media, Eustachian dysfunction, repeated infections, possibly genetic variants or coagulation changes.[15][16][17] TLR4 promotes inflammation/bone destruction.[5] Pediatric cases more aggressive.[12]

Diagnosis

  • Clinical: Otoscopy shows white mass, retraction pockets, perforations; persistent otorrhea raises suspicion.[1][6]
  • Imaging: HRCT defines bony erosion (sensitivity 83.3%, specificity 58.3%); DWI-MRI superior for soft tissue (sensitivity/specificity 91.6%).[2][18] Correlate with intraoperative findings.
  • Histopathology: Stratified squamous epithelium, keratin debris, inflammation.[3][19]
  • Microbiology: Pseudomonas aeruginosa (31%), S. aureus (19%); superinfection drives aggression.[20][21]

No vital signs provided; if available, restate exactly for analysis.

Scientific Evidence

  • HRCT/MRI study (n=40): MRI outperforms HRCT in cholesteatoma detection.[2]
  • Pathogenesis: Hyperproliferation, EMT via osteopontin/HIF-1α; TLR4-mediated osteoclastogenesis.[5][22][23]
  • Staging: EAONO/JOS for severity/removal difficulty.[10]
  • Recurrence: 10-20% post-surgery; linked to incomplete excision.[24]

Treatment and Clinical Decision-Making

Surgical excision is definitive; medical therapy ineffective.[1][25]

Approach Indications Outcomes
Canal Wall Up (CWU) Limited disease, good mastoid aeration Hearing preservation; higher recurrence risk.
Canal Wall Down (CWDT) Extensive cholesteatoma, poor aeration Lower recurrence; poorer hearing.[26]
Endoscopic Congenital/early; transcanal Excellent for pediatric; reduced morbidity.[27][25]
  • Guidelines: Timely surgery per EAONO/JOS staging; mastoidectomy ± ossiculoplasty.[10][24]
  • Decisions: Stage via CT/MRI; CWDT for complications; second-look for CWU.[26]
  • Novel: Mucosal regeneration via cell sheets post-resection.[28]

Patient Safety and Risks

  • Complications: Recurrence (matrix remnants), iatrogenic hearing loss, facial nerve injury, CSF leak.[24][14]
  • Side Effects: Postoperative otorrhea, vertigo; monitor with audiometry, imaging.
  • Monitoring: Regular otoscopy, audiograms; antibiotics for infection (e.g., vs. Pseudomonas).[20]
  • Contraindindications: Active intracranial infection (stabilize first).[13][29]
  • Variability: Pediatrics more aggressive; genetic/microbiome factors affect response.[3][21][16]

Health Impact

Untreated: Irreversible deafness (77% moderate), ossicular/facial damage, intracranial spread (abscess mortality risk).[30][13] Surgery restores function in most; long-term: 70-90% hearing gain possible.[26]

Fuentes

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11464026/
  2. http://www.radiologypaper.com/archives/2019.v2.i2.B.77
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC9441961/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC9731553/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4671024/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC8680935/
  7. https://www.semanticscholar.org/paper/e62d7acee8394ae932764cdfb3771b54eb136c9c
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC9449072/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC1769393/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC6081285/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC9442758/
  12. https://journal.nds.ox.ac.uk/index.php/JNDS/article/download/152/73
  13. https://www.cambridge.org/core/product/identifier/S0022215116005077/type/journal_article
  14. https://rjor.ro/diagnosis-and-therapeutic-management-of-complicated-middle-ear-cholesteatoma-a-narrative-review/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC1069039/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC9868167/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC9884986/
  18. http://link.springer.com/10.1007/s00405-011-1577-z
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC9445956/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC2816367/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC11822790/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC10960243/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC11135870/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC11594670/
  25. https://www.semanticscholar.org/paper/5c1ec370b6f738688c3b5d7edb8779f8415f8a5e
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC9411471/
  27. http://juniperpublishers.com/gjo/pdf/GJO.MS.ID.556049.pdf
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC5665617/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC9561596/
  30. https://www.banglajol.info/index.php/MEDISCOPE/article/download/34999/23595
  31. https://www.semanticscholar.org/paper/6b74f60c172e57d3ac5e739ee5db7c1271d9e8c5
  32. https://www.semanticscholar.org/paper/c14f52b1da42d3e42006edde0e22d29d99eb5e6a
  33. https://www.semanticscholar.org/paper/e9d6e041e8803b4658596d00735e9f1b9debd038
  34. https://www.bmj.com/lookup/doi/10.1136/bmj.325.7373.1159
  35. https://www.semanticscholar.org/paper/4979cc56082e942a9d30f6610151b5769d56b35d
  36. https://www.cureus.com/articles/116977-diagnosis-and-treatment-modalities-of-cholesteatomas-a-review.pdf
  37. https://www.mdpi.com/2077-0383/13/22/6791/pdf?version=1731391356
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC3095160/
  39. https://publications.goettingen-research-online.de/bitstream/2/91926/1/2161-119X-S5-001.pdf
  40. http://juniperpublishers.com/gjo/pdf/GJO.MS.ID.555998.pdf
  41. https://journals.lww.com/10.1097/MD.0000000000037511
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC5408875/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC5205518/
  44. https://www.clinical-medicine.panafrican-med-journal.com/content/article/1/11/full/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC7837648/
  46. https://www.genesispub.org/resource/images/articles/pdf258.pdf
  47. https://www.banglajol.info/index.php/BJO/article/download/53214/37574
  48. http://downloads.hindawi.com/journals/criot/2013/865043.pdf
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC10474165/
  50. http://medicaljournal.gazi.edu.tr/index.php/GMJ/article/view/2875

Respuesta generada por inteligencia artificial a partir de las fuentes citadas. Verifica las fuentes antes de aplicarla.

¿Tienes una pregunta sobre tu propio caso? Itaca responde con fuentes en segundos.

Hacer una pregunta

Más preguntas sobre enfermedades otorrinolaringológicas